Search clinical trials for: Cholangiocarcinoma Non-resectable

Total 847 results

Steba Biotech S.A.

Terminated

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Cholangiocarcinoma

France
Region Stockholm

Recruiting

Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents

Bile Duct Cancer | Duodenal Cancer | Pancreatic Cancer Non-resectable | Papillary Carcinoma

Sweden
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Universitätsklinikum Köln, Germany; Universitätsklinikum Düsseldorf...

Not yet recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma | Unresectable Perihilar or Ductal CCA

Germany
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
West China Hospital

Not yet recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Cholangiocarcinoma
Singlera Genomics Inc.
Fudan University; Beijing Friendship Hospital; Shanxi Provincial Cancer Hospital and other collaborators

Not yet recruiting

INSPIRE: A Multi-Cancer Early Detection Study (INSPIRE)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Endometrial Cancer | Liver Cancer
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Cholangiocarcinoma | FGFR2 Fusion

United States
The Christie NHS Foundation Trust
University College London Hospitals; University College, London; Royal Free Hospital...

Not yet recruiting

Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma (EMPHATIC)

Cholangiocarcinoma
Mayo Clinic

Recruiting

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Zhiyong Huang

Not yet recruiting

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
University Hospital, Bordeaux

Not yet recruiting

Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy (PROTEOBILE)

Cholangiocarcinoma

France
Yongyi Zeng

Not yet recruiting

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

Intrahepatic Cholangiocarcinoma
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Colorectal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Prostate Cancer | Gastric Adenocarcinoma | Cholangiocarcinoma | Triple Negative Breast Cancer | Endometrial Adenocarcinoma | Appendiceal Adenocarcinoma
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
City of Hope Medical Center

Recruiting

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) (LyMIC)

Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic | Cholangiocarcinoma Resectable | Cholangiocarcinoma; Liver

United States, Japan
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Francesco De Cobelli
A.O. Ospedale Papa Giovanni XXIII; Cardarelli Hospital; AOU Pisana, Pisa, Italy

Recruiting

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE)

Intrahepatic Cholangiocarcinoma

Italy
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Rigshospitalet, Denmark

Recruiting

Prognostic Factors for Survival in Patients With Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Soonchunhyang University Hospital

Not yet recruiting

Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures (Spy+IDUS)

Cholangiocarcinoma | Biliary Stricture
Beijing Friendship Hospital

Recruiting

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Thyroid Cancer | Liver Cancer

China
Cook Research Incorporated

Not yet recruiting

EchoTip AcuCore Post-Market Clinical Study

Adenocarcinoma | Hepatocellular Carcinoma | Neuroendocrine Tumors | Cholangiocarcinoma | Metastasis | Chronic Pancreatitis | Autoimmune Pancreatitis | Malignant Lymphoma
Mara Veenstra, MD
UMC Utrecht; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Not yet recruiting

The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma (FAPIChol)

Cholangiocarcinoma
National Cancer Institute, Naples

Recruiting

Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma

Italy
City of Hope Medical Center

Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer (ELUCIDATE)

Hepatocellular Carcinoma | Primary Liver Cancer | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Hepatic Cancer | Hepatic Carcinoma | Primary Liver Carcinoma

United States, Japan
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
Orlando Health, Inc.

Recruiting

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Pancreatic Cancer | Bile Duct Cancer | Bile Duct Diseases | Gastrointestinal Cancer | Lymph Node Disease | Pancreatic Cyst | Pancreatic Disease | Gastrointestinal Tumor | Submucosal Tumor of Gastrointestinal Tract

United States
Fudan University

Recruiting

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Oslo University Hospital

Recruiting

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (TOMCAT)

Intrahepatic Cholangiocarcinoma | Chemotherapy Effect

Norway
Rigshospitalet, Denmark

Recruiting

Open Versus Laparoscopic Ablation of Liver Malignancies (OPTIMAL)

Hepatocellular Carcinoma | Cholangiocarcinoma | Liver Metastases

Denmark
Massachusetts General Hospital
Boehringer Ingelheim; Incyte Corporation

Recruiting

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor | Unresectable Solid Tumor

United States
Nanfang Hospital, Southern Medical University

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Lei ZHAO

Recruiting

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Intrahepatic Cholangiocarcinoma

China
West China Hospital

Recruiting

A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Machine Learning

China
Oslo University Hospital

Recruiting

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy

Metastatic Colorectal Cancer | Cholangiocarcinoma | Pancreas Adenocarcinoma

Norway
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Jazz Pharmaceuticals

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer | HER2 Gene Mutation

United States, Puerto Rico
Peking University Third Hospital
Beijing Tsinghua Changgeng Hospital

Recruiting

Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) (ECCBILE)

Bile Duct Cancer | Pancreas Cancer | Biliary Stricture

China
Insel Gruppe AG, University Hospital Bern
Swiss Cancer League

Not yet recruiting

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer (Ablatio)

Bile Duct Cancer

Switzerland
University of Miami
The V Foundation

Recruiting

Targeted Navigation in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Hepatobiliary Cancer

United States
UTC Therapeutics Inc.
Peking University Cancer Hospital & Institute

Recruiting

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Colorectal Cancer | Pancreatic Cancer | Rectal Cancer | Malignant Mesothelioma | Bile Duct Cancer | Breast Cancer Female | Ovary Cancer

China
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Lung Cancer | Non Small Cell Lung Cancer

United States
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China
Liu Huang

Recruiting

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Stomach Cancer | Breast Cancer | Pancreatic Adenocarcinoma | Lung Cancer | Cholangiocarcinoma | Esophageal Carcinoma

China
Zhang Xiaofeng,MD
Zeno Therapeutics Pte. Ltd

Not yet recruiting

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Pancreatic Cancer | Advanced Biliary Cancer
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China

Search clinical trials for: Cholangiocarcinoma Non-resectable

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations